Clinical trials: PTCL
PTCL, T Cell Lymphoma
A Multi-center, Prospective, Registry Study to Analyze the Clinical Characteristics and Prognosis of Different Molecular Subtypes of Peripheral T-cell Lymphoma.
A multi-center, prospective, registry study to analyze the clinical characteristics and prognosis of different molecular subtypes of peripheral T-cell lymphoma.
- Trial name
- EXCELLENT (NCT07657572)
- Volunteers
- 1,000 people
- Sponsor
- Ruijin Hospital
Peripheral T-cell Lymphoma (PTCL)
New Genotype-guided Treatment in Newly Diagnosed PTCL
This is a phase I/II study evaluate the safety and efficacy targeted agents in combination with standard CHOP in new genotypic subtypes in treatment naive peripheral T-cell lymphoma. Phase I is to confirm RP2D of targeted agent.
- Trial name
- G08 (NCT07706959)
- Testing
- Azacitidine plus Selinexor with CHOP, Decitabine plus Selinexor with CHOP, Zeprumetostat plus chidamide with CHOP
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Ruijin Hospital
Peripheral T-cell Lymphoma
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
This is a phase 3, open-label, randomized, multinational study to evaluate the anti-tumor efficacy of golidocitinib versus investigator's choice in adult patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL).
- Trial name
- NCT07234162
- Testing
- Golidocitinib, Chidamide, Gemcitabine
- Where
- 51 sites in China, Taiwan and 1 more
- Volunteers
- 218 people
- Sponsor
- Dizal Pharmaceuticals